ArticleCancer discovery2017
Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma.
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Mitochondrial creatine kinase 1 regulates the cell cycle in non-small cell lung cancer via activation of cyclin-dependent kinase 4.Respiratory research · 2023Article
- NcRNA-regulated CAPZA1 associated with prognostic and immunological effects across lung adenocarcinoma.Frontiers in oncology · 2022Article
- LINC01089 suppresses lung adenocarcinoma cell proliferation and migration via miR-301b-3p/STARD13 axis.BMC pulmonary medicine · 2021Article
- LINC02418 promotes malignant behaviors in lung adenocarcinoma cells by sponging miR-4677-3p to upregulate KNL1 expression.BMC pulmonary medicine · 2020Article
- Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis.BioMed research international · 2020Article
- Matrix Metalloproteinase 11 Is a Potential Therapeutic Target in Lung Adenocarcinoma.Molecular therapy oncolytics · 2019Article
- LncRNA TP73-AS1 promoted the progression of lung adenocarcinoma via PI3K/AKT pathway.Bioscience reports · 2019Article
- Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
<b/> Assessing the benefit of routine panel-based genomic sequencing of tumor tissue remains a critical need in clinical oncology. Jordan and coauthors report on 860 patients with metastatic or recurrent lung adenocarcinoma from a single institution with prospectively sequenced tumors using a targeted gene panel of >300 genes to guide therapy. Their results suggest that early prospective tumor sequencing, including non-standard-of-care predictive biomarkers combined with careful clinical annotation, can guide therapy, improve clinical outcomes, and accelerate the development of biomarkers and drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.